TriangleCabozantinib + Enfortumab Vedotin (NCT04878029)
Cabozantinib + Enfortumab Vedotin trial for Locally Advanced or Metastatic Urothelial Cancer (NCT04878029). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
Lo que dice el vídeo
Lee la transcripción
This trial is for adults with urothelial cancer, such as bladder cancer, that is locally advanced or has spread.
The idea: combine cabozantinib, a pill that may stop tumor growth by blocking enzymes cells need, with enfortumab vedotin, given by vein. Enfortumab vedotin is an antibody linked to a toxic agent. The antibody attaches to nectin-4 on cancer cells and delivers the toxin.
The study looks for the best dose, possible benefits, and side effects.
This phase 1 study plans 32 patients. At Emory University's Winship Cancer Institute in Atlanta, Mehmet Bilen leads it.
Public record; not medical advice.
¿Ya estás en un ensayo?
Se convierte en un proyecto que hay que manejar: citas, estudios de imagen, análisis, efectos secundarios y papeleo. Triangle lo mantiene organizado en un solo lugar, para ti o para quien te ayuda.
Organizar mi ensayoPrueba gratuita de 7 días, después $9 al mes. Cancela cuando quieras.
Cómo funcionan estos ensayos: qué es de verdad la fase 1 · preguntas frecuentes No es evidencia clínica.